tiprankstipranks
LungLife AI Gains Medicare Coverage for LungLB® Test
Company Announcements

LungLife AI Gains Medicare Coverage for LungLB® Test

LungLife AI, Inc. (GB:LLAI) has released an update.

Don't Miss Our Christmas Offers:

LungLife AI, Inc., a company pioneering in diagnostic solutions for lung cancer, has announced Medicare’s finalized coverage for their LungLB® test, which aids in diagnosing lung cancer from indeterminate pulmonary nodules. This coverage is a significant milestone for LungLife, allowing them to receive payment for tests conducted from September 22, 2024, onwards and paving the way for broader commercialization. The company views this development as a key opportunity to make early lung cancer detection more widely available and reimbursable by Medicare.

For further insights into GB:LLAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskLungLife AI Advances Toward LungLB® Commercialization
TipRanks UK Auto-Generated NewsdeskLungLife AI Confident Amid Board Change
TipRanks UK Auto-Generated NewsdeskLungLife AI Revamps Stock Options Amid Cancer Test Advances
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App